CN103585312B - A kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof - Google Patents
A kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof Download PDFInfo
- Publication number
- CN103585312B CN103585312B CN201310525436.8A CN201310525436A CN103585312B CN 103585312 B CN103585312 B CN 103585312B CN 201310525436 A CN201310525436 A CN 201310525436A CN 103585312 B CN103585312 B CN 103585312B
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- fruit
- diabetes
- gmel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 58
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 65
- 229940079593 drug Drugs 0.000 claims abstract description 44
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 38
- 241000688694 Cheilanthes argentea Species 0.000 claims abstract description 25
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 20
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 20
- 241001230539 Spiraea alpina Species 0.000 claims abstract description 19
- 240000007133 Cordia dichotoma Species 0.000 claims abstract description 17
- 235000005943 Cordia dichotoma Nutrition 0.000 claims abstract description 17
- 238000000605 extraction Methods 0.000 claims description 19
- 239000012467 final product Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 238000003809 water extraction Methods 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000008280 blood Substances 0.000 description 33
- 210000004369 blood Anatomy 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 22
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 150000004676 glycans Chemical class 0.000 description 9
- 229920001282 polysaccharide Polymers 0.000 description 9
- 239000005017 polysaccharide Substances 0.000 description 9
- 108010007622 LDL Lipoproteins Proteins 0.000 description 8
- 102000007330 LDL Lipoproteins Human genes 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000005180 public health Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 5
- 229930182837 (R)-adrenaline Natural products 0.000 description 5
- 229960005139 epinephrine Drugs 0.000 description 5
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 208000031971 Yin Deficiency Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 239000002023 wood Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- LNWOKEZJIRLIDO-ZJGHDVHGSA-N (E)-5-[(1S,4aR,6S,8aR)-6-hydroxy-5,5,8a-trimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]-3-methylpent-2-enoic acid Chemical compound CC1(C)[C@@H](O)CC[C@]2(C)[C@@H](CCC(/C)=C/C(O)=O)C(=C)CC[C@H]21 LNWOKEZJIRLIDO-ZJGHDVHGSA-N 0.000 description 2
- LNWOKEZJIRLIDO-UHFFFAOYSA-N 15-Carboxylic acid-(ent-3beta,13Z)-8(17),13-Labdadien-3,15-diol Natural products CC1(C)C(O)CCC2(C)C(CCC(C)=CC(O)=O)C(=C)CCC21 LNWOKEZJIRLIDO-UHFFFAOYSA-N 0.000 description 2
- XVVBVBKVMMNZHB-LFYBBSHMSA-N 9-[(e)-3-methyl-4-(4-methyl-5-oxo-2h-furan-2-yl)but-2-enoxy]furo[3,2-g]chromen-7-one Chemical compound C=12OC=CC2=CC=2C=CC(=O)OC=2C=1OC\C=C(/C)CC1OC(=O)C(C)=C1 XVVBVBKVMMNZHB-LFYBBSHMSA-N 0.000 description 2
- 241000133570 Berberidaceae Species 0.000 description 2
- 241001518358 Berberis nummularia Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 229920001543 Laminarin Polymers 0.000 description 2
- 244000241838 Lycium barbarum Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 2
- 241000219100 Rhamnaceae Species 0.000 description 2
- 241000848722 Rhamnella gilgitica Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 240000002299 Symphytum officinale Species 0.000 description 2
- 235000005865 Symphytum officinale Nutrition 0.000 description 2
- 241001506047 Tremella Species 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 235000019636 bitter flavor Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- -1 flavone compound Chemical class 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000221377 Auricularia Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 241000668709 Dipterocarpus costatus Species 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 240000000588 Hericium erinaceus Species 0.000 description 1
- 235000007328 Hericium erinaceus Nutrition 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000206609 Porphyra Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000029224 Thoracic injury Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000035611 feeding Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004345 fruit ripening Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Abstract
The present invention relates to a kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof, it is characterized in that: this pharmaceutical composition is made up of following crude drug by weight: 3-7 part, wall tapestry 2-4 part, fruit of Cordia dichotoma Forst. f. 3-5 part, the Aleuritopteris argentea (Gmel.) Fee 2-4 parts such as Radix Berberidis Amurensis fruit 8-15 part, Spiraea alpina 4-6 part, Song Sheng.Drug regimen of the present invention has good using value to treatment diabetes.
Description
Technical field
The invention belongs to field of medicaments, relate to a kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof.
Background technology
Along with the aging of world population, diabetes have become a kind of commonly encountered diseases, frequently-occurring disease, and in industrially developed country, its sickness rate is in rising trend.According to statistics, about there are 1.5 hundred million diabeticss in the whole world, and 80% is non-insulin-dependent diabetes mellitus (2 type), and wherein China about has 3,000 ten thousand.The death toll caused by diabetic complication has been the rank rear the 3rd of cardiovascular and cerebrovascular disease, cancer of continuing in developed country, causes the great attention of countries in the world, studies one after another to the pathogenesis, medical treatment etc. of diabetes.Because the type 1 diabetes cause of disease is substantially clear and definite, only need supplementation with insulin, type 2 diabetes mellitus is then more complicated, and what current China medical circle was taked it is the complex treatment measure comprising dietetic therapy, Drug therapy and other complementary therapy.Although Western medicine emerges in an endless stream, can not tackle the problem at its root, and western medicine has certain side effect and " failure in treatment ".TCM Treatment of Diabetes is with a long history, and clinical experience enriches, evident in efficacy, has become recent domestic study hotspot.The understanding of Chinese medicine to diabetes is different from doctor trained in Western medicine, and the traditional Chinese medical science emphasizes Overall View, with the essence of the change of both yin, yangs reflection disease.Normal body is " YIN and YANG in a relative equilibrium ", equilibrium between yin and yang, and namely organismic internal environment maintains stable state, and carbohydrate metabolism also remains stable; And the toxic and side effects of Chinese medicine is relatively little, patient can long-term taking, and this is the advantage of the uniqueness that Western medicine can not be compared.
The traditional Chinese medical science thinks that diabetes to be burnt cloudy losing by lung, stomach, the dirty heat of kidney three, water paddy transfer not normal caused by.Its base
This pathogenesis is cloudy body fluid deficiency consumption, scorching inclined Sheng, and deficiency of kidney-YIN is originally, and lung dryness of the stomach heat is mark, sick then cloudy damage QI consumed sun wound of a specified duration, and causes impairment of both QI and YIN, deficiency in both YIN and YANG, venation block, and the mistake of muscle arteries and veins is supported, and internal organs are impaired, gradually causes a series of double disease of appearance.
The course of disease of diabetes is processes of deficiency of YIN affecting YANG.Dialectical with the moon, from gently to heavy, be then the conversion of the deficiency of YIN-deficiency of both QI and YIN-deficiency of both YIN and YANG.And venation block is through the overall process of primary disease and double disease.
In recent years, some scholars have inquired into the relation of TCM Syndrome Differentiation of Diabetes and clinical biochemistry indications.From changes such as islet function, blood lipid level, sexual hormones, corticoid level, immunologic function machine hemorheologys, the dependency that observation diabetes typing and above index change, find the ANOMALOUS VARIATIONS of various index, from gently to heavy, how with the deficiency of YIN-deficiency of both QI and YIN-deficiency of both YIN and YANG future development.Embody the material base that diabetes typing is inquired in the combination of Chinese and Western medicine.
Determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs is the marrow of theory of Chinese medical science.The traditional Chinese medical science, according to the main pathogenesis of diabetes, distinguishes specimen weight that the is scorching and deficiency of YIN, payes attention to yin nourishing during medication, has scorching person then must heat clearing away, and yang blood and qi all loses, then yang blood and qi mending.According to modern pharmacology concept, mainly as follows to Chinese medicine diabetes Effect study.Single medicinal material: Rhizoma Coptidis and berberine, Fructus Momordicae charantiae, Radix Ginseng, the Radix Astragali, Radix Scutellariae, Folium Mori, herbal polysaccharide (as tremella polysaccharide, tremella polysaccharide spore, Auricularia polysaccharide, Hericium erinaceus polysaccharide, Porphyra Polysaccharide, Radix Ophiopogonis polysaccharide, laminaran (laminarin), lycium barbarum polysaccharide-X, lycium barbarum polysaccharide-D, Fructus Caricae polysaccharide and Cortex Moutan polysaccharide etc.), silymarin, Radix Et Rhizoma Rhei.In addition, oral administration of flavonoids puerarin (puerarin) or clausenacoumarine (clausenacoumarine) hyperglycemia to ALX animal also have reducing effect.The basic principle of TCM treatment of diabetes can be summarized as: nourishing YIN and clearing away heat, supplementing QI and nourishing YIN, kidney and spleen invigorating and blood circulation promoting and blood stasis dispelling etc.Conventional classic prescriptions has Ginseng Baihu Decoction, LIUWEI DIHUANG WAN, eight Dihuang Wans and a thousand pieces of gold coptis teeta pill etc., according to different pattern of syndrome and above-mentioned rule for the treatment of prescription or add and subtract with ancient prescription.
Radix Berberidis Amurensis fruit is the dry mature fruit of Berberidaceae plant Berberis nummularia Bge. BerberisnummulariaBge..Record in 1998 " Drug Standard of Ministry of Public Health of the Peoples Republic of China Uigurs medicine fascicle ".Its property put down, have stomach invigorating and in, promoting the production of body fluid to quench thirst, effect of heat-clearing and toxic substances removing.For dyspepsia, under dysentery is rushed down, thirsty, aphtha, pharyngitis.
Spiraea alpina is dried floral, the leaf of rosaceous plant Spiraea alpina SpiraeaalpinaTurcz..Florescence gathers, and dries.Record in 1998 " Drug Standard of Ministry of Public Health of the Peoples Republic of China mongolian medicine fascicle " cool in nature, sweet in the mouth.Have bone heat clearly, promote the production of body fluid, hemostasis, holds back effect of yellow fluid.For controlling skin infection, grasserie, ascites, pulmonary congestion, metrorrhagia.
Song Sheng etc. are the desiccated wood of the Fructus Rhamni parvifoliae RhamnusparvifoliaBunge of Rhamnaceae plant Rhamnella gilgitica RhamnellagilgiticaMansf.etMelch..The whole year all can gather, and except debarking, the section of being sawn into, dries after riving.Record in " Drug Standard of Ministry of Public Health of the Peoples Republic of China Tibetan medicine (first) ", standard number: WS3-BC-0055-95.Cool in nature, mildly bitter flavor.There is removing heat from blood, effect of detumescence.For rheumatoid arthritis, grasserie, the many disorders of blood of high mountain.
Fruit of Cordia dichotoma Forst. f. is the dry mature fruit of comfrey rag wood CordiadichotomaForst.f..Pluck during fruit maturation in autumn, dry.Record in 1998 " Drug Standard of Ministry of Public Health of the Peoples Republic of China Uigurs medicine fascicle ".Property is put down.Have ripe and remove abnormal phlegm, regulate bile matter balance, nourishing the lung to arrest cough, the chest stuffiness relieving reduces phlegm.More than for coughing, bile matter is vigorous, and expectoration is not well, the dry itching throat of larynx.
Wall tapestry is the dry thallus of lichens Teloshistaceae plant wall tapestry Theloschestesflavicans (Sw.) Norm.After collection, removing earth, dries.Record in " Drug Standard of Ministry of Public Health of the Peoples Republic of China Tibetan medicine (first) ", standard number: WS3-BC-0125-95.Cool in nature, bitter in the mouth.There is heat extraction, effect of removing toxic substances.For lung-heat, liver-heat, arteries and veins heat, scorchingly hot.
Aleuritopteris argentea (Gmel.) Fee system Sinopteridaceae plant Aleuritopteris argentea (Gmel.) Fee (Aleuritopterisargentea(Gmel.) Fee) dry herb.Autumn gathers, and removing impurity dries.Record in 1998 " Drug Standard of Ministry of Public Health of the Peoples Republic of China mongolian medicine fascicle ".Its property is put down, and mildly bitter flavor, has the effects such as improving eyesight, wound healing, hemostasis, promoting blood flow to regulate menstruation, cough-relieving, dampness removing, removing toxic substances and promoting subsidence of swelling, can be used for conjunctival congestion, visual deterioration, thoracic injury, bone injury, pulmonary tuberculosis cough, haematemesis.The common drug of the minority areas such as illiteracy is hidden for China.But about the basic research of Aleuritopteris argentea (Gmel.) Fee is still very limited, the follow-up promotion and application of this medical material are restricted.Modern study shows, Aleuritopteris argentea (Gmel.) Fee contains alepterolic acid (alepterolicacid), sucrose (sucrose) and flavone compound, and other chemical compositions are not quite clear; Pharmacological research shows, Aleuritopteris argentea (Gmel.) Fee flavone is that a kind of natural effective free radical scavenger Aleuritopteris argentea (Gmel.) Fee flavone has very strong scavenging action to hydroxyl radical free radical, ultra-oxygen anion free radical, hydrogen peroxide, its EC
50be respectively 0.0099,0.0060 and 0.0190mg/mL, and in concentration-dependent relation, other pharmacological actions have no report.
Namely existing document and patent etc., there is not yet pharmaceutical composition of the present invention: the compositions of Radix Berberidis Amurensis fruit, Spiraea alpina, Song Sheng etc., wall tapestry, fruit of Cordia dichotoma Forst. f., Aleuritopteris argentea (Gmel.) Fee composition is for the preparation of the report for the treatment of diabetes medicament.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof.
The present invention is achieved through the following technical solutions:
The present invention is raw materials used
Radix Berberidis Amurensis fruit is the dry mature fruit of Berberidaceae plant Berberis nummularia Bge. BerberisnummulariaBge..Spiraea alpina is dried floral, the leaf of rosaceous plant Spiraea alpina SpiraeaalpinaTurcz.; Song Sheng etc. are the desiccated wood of the Fructus Rhamni parvifoliae RhamnusparvifoliaBunge of Rhamnaceae plant Rhamnella gilgitica RhamnellagilgiticaMansf.etMelch.; Fruit of Cordia dichotoma Forst. f. is the dry mature fruit of comfrey rag wood CordiadichotomaForst.f.; Wall tapestry is the dry thallus of lichens Teloshistaceae plant wall tapestry Theloschestesflavicans (Sw.) Norm; Aleuritopteris argentea (Gmel.) Fee system Sinopteridaceae plant Aleuritopteris argentea (Gmel.) Fee (Aleuritopterisargentea(Gmel.) Fee) dry herb.
A kind of pharmaceutical composition for the treatment of diabetes of the present invention, is characterized in that: be made up of following crude drug by weight: 3-7 part, wall tapestry 2-4 part, fruit of Cordia dichotoma Forst. f. 3-5 part, the Aleuritopteris argentea (Gmel.) Fee 2-4 parts such as Radix Berberidis Amurensis fruit 8-15 part, Spiraea alpina 4-6 part, Song Sheng.
Preferred compositions proportioning: a kind of pharmaceutical composition for the treatment of diabetes of the present invention, is characterized in that: be made up of following crude drug by weight: Radix Berberidis Amurensis fruit 10 parts, Spiraea alpina 5 parts, Song Sheng etc. 5 parts, wall tapestry 3 parts, fruit of Cordia dichotoma Forst. f. 4 parts, Aleuritopteris argentea (Gmel.) Fee 3 parts.
A kind of pharmaceutical composition for the treatment of diabetes of the present invention, preparation method is: each crude drug is mixed, with water extraction, Extracting temperature 50 DEG C-100 DEG C, extraction time is 1-4 time, and each extraction time is 1-4 hour, and each solvent load is 6-15 times of each crude drug gross weight; Filter, merge extractive liquid, concentrated, dry, to obtain final product.
A kind of pharmaceutical composition for the treatment of diabetes of the present invention, preferred preparation method is: each crude drug is mixed, with water extraction, Extracting temperature 93 DEG C, extraction time is 2 times, and each extraction time is 2 hours, and each solvent load is 12 times of each crude drug gross weight; Filter, merge extractive liquid, concentrated, dry, to obtain final product;
A kind of pharmaceutical composition for the treatment of diabetes of the present invention, by adding the various adjuvants that pharmaceutics allows, making and pharmaceutics makes powder or tablet or pill or capsule.
The pharmaceutical composition for the treatment of diabetes of the present invention, the treatment diabetes medicament formed with chemical drugs or Chinese medicine or natural drug.
Pharmaceutical composition provided by the invention, by blood sugar lowering, regulating blood lipid action research, result shows, has remarkable hypoglycemic activity to diabetic mice, can regulate diabetic mice blood lipid level simultaneously.Compare with model group, pharmaceutical composition of the present invention significantly can reduce alloxan and cause blood glucose in diabetic mice value (P<0.05), and significantly can reduce epinephrine and cause blood glucose in diabetic mice value (P<0.05).Administration group mice triacylglycerol, low density lipoprotein, LDL content significantly decline (P<0.05), and hdl concentration significantly raises (P<0.05).
Detailed description of the invention
Treat diabetes medicament composition and method of making the same below by specific experiment example and embodiment to one of the present invention to be described further, but be not limited to the present invention.
Embodiment 1: pharmaceutical composition and preparation method thereof
Pharmaceutical composition is made up of following crude drug by weight: Radix Berberidis Amurensis fruit 10kg, Spiraea alpina 5kg, Song Sheng etc. 5kg, wall tapestry 3kg, fruit of Cordia dichotoma Forst. f. 4kg, Aleuritopteris argentea (Gmel.) Fee 3kg;
Pharmaceutical composition preparation method: each crude drug is mixed, with water extraction, Extracting temperature 93 DEG C, extraction time is 2 times, and each extraction time is 2 hours, and each solvent load is 12 times of each crude drug gross weight; Filter, merge extractive liquid, concentrated, dry, to obtain final product.
Embodiment 2: pharmaceutical composition and preparation method thereof
Pharmaceutical composition is made up of following crude drug by weight: Radix Berberidis Amurensis fruit 8kg, Spiraea alpina 6kg, Song Sheng etc. 3kg, wall tapestry 4kg, fruit of Cordia dichotoma Forst. f. 3kg, Aleuritopteris argentea (Gmel.) Fee 4kg;
Pharmaceutical composition preparation method: each crude drug is mixed, with water extraction, Extracting temperature 50 DEG C, extraction time is 4 times, and each extraction time is 1 hour, and each solvent load is 6 times of each crude drug gross weight; Filter, merge extractive liquid, concentrated, dry, to obtain final product.
Embodiment 3: pharmaceutical composition and preparation method thereof
Pharmaceutical composition is made up of following crude drug by weight: Radix Berberidis Amurensis fruit 15kg, Spiraea alpina 4kg, Song Sheng etc. 7kg, wall tapestry 2kg, fruit of Cordia dichotoma Forst. f. 5kg, Aleuritopteris argentea (Gmel.) Fee 2kg;
Pharmaceutical composition preparation method: each crude drug is mixed, with water extraction, Extracting temperature 100 DEG C, extraction time is 1 time, and each extraction time is 4 hours, and each solvent load is 15 times of each crude drug gross weight; Filter, merge extractive liquid, concentrated, dry, to obtain final product.
Embodiment 4: pharmaceutical composition and preparation method thereof
Pharmaceutical composition is made up of following crude drug by weight: Radix Berberidis Amurensis fruit 10kg, Spiraea alpina 5kg, Song Sheng etc. 5kg, wall tapestry 3kg, fruit of Cordia dichotoma Forst. f. 4kg, Aleuritopteris argentea (Gmel.) Fee 3kg;
Pharmaceutical composition preparation method: each crude drug was pulverized 100 mesh sieves, mixing, makes granule with Diluted Alcohol, dry, adds starch, magnesium stearate, tabletting, to obtain final product.
Embodiment 5: pharmaceutical composition and preparation method thereof
Pharmaceutical composition is made up of following crude drug by weight: Radix Berberidis Amurensis fruit 10kg, Spiraea alpina 5kg, Song Sheng etc. 5kg, wall tapestry 3kg, fruit of Cordia dichotoma Forst. f. 4kg, Aleuritopteris argentea (Gmel.) Fee 3kg;
Pharmaceutical composition preparation method: each crude drug was pulverized 150 mesh sieves, mixing, makes granule with Diluted Alcohol, dry, adds magnesium stearate, encapsulated, to obtain final product.
Embodiment 6: pharmaceutical composition and preparation method thereof
Pharmaceutical composition is made up of following crude drug by weight: Radix Berberidis Amurensis fruit 10kg, Spiraea alpina 5kg, Song Sheng etc. 5kg, wall tapestry 3kg, fruit of Cordia dichotoma Forst. f. 4kg, Aleuritopteris argentea (Gmel.) Fee 3kg;
Pharmaceutical composition preparation method: each crude drug is mixed, with water extraction, Extracting temperature 93 DEG C, extraction time is 2 times, and each extraction time is 2 hours, and each solvent load is 12 times of each crude drug gross weight; Filter, merge extractive liquid, concentrated, dry, add dextrin appropriate, granulate, granulate, sieves, and makes granule.
Embodiment 7: pharmaceutical composition and preparation method thereof
Pharmaceutical composition is made up of following crude drug by weight: Radix Berberidis Amurensis fruit 10kg, Spiraea alpina 5kg, Song Sheng etc. 5kg, wall tapestry 3kg, fruit of Cordia dichotoma Forst. f. 4kg, Aleuritopteris argentea (Gmel.) Fee 3kg;
Pharmaceutical composition preparation method: each crude drug is mixed, with water extraction, Extracting temperature 93 DEG C, extraction time is 2 times, and each extraction time is 2 hours, and each solvent load is 12 times of each crude drug gross weight; Filter, merge extractive liquid, concentrated, dry, to obtain final product.
Add customary adjuvant and make various dosage form on pharmaceutics.
Experimental example 1: pharmaceutical composition blood sugar lowering, regulating blood lipid action
1. medicine and reagent: the pharmaceutical composition that experimental drug thing is embodiment 1, embodiment 4 prepares, is numbered pharmaceutical composition 1, pharmaceutical composition 4.Alloxan (Sigma Co., USA); Glucose kit (Zhongsheng Beikong Biological Science & Technology Co., Ltd., lot number: 102401.201010); T-CHOL test kit (Zhongsheng Beikong Biological Science & Technology Co., Ltd., lot number: 101051.201007): triacylglycerol test kit (Zhongsheng Beikong Biological Science & Technology Co., Ltd., lot number: 104101.201008); High density lipoprotein test kit (Zhongsheng Beikong Biological Science & Technology Co., Ltd., lot number: 100361) low density lipoprotein, LDL test kit (Zhongsheng Beikong Biological Science & Technology Co., Ltd., lot number: 100271); Glibenclamide (Tianjin Lisheng Pharmaceutical Co., Ltd., lot number: 1003013); All the other agents useful for same are analytical pure.
2. laboratory animal: Kunming mouse, body weight 18-22g, cleaning grade, male and female half and half, are provided by Mountain Western Medicine S University's Experimental Animal Center.It is consistent that this tests all animal feedings, starts to test front 3d and put the raising of this laboratory observation, freely ingest, drink water.Each group of feedstuff is originated all identical with drinking water.
3. instrument: rotary evaporator RE-52AA (Shanghai Yarong Biochemical Instrument Plant); 752 ultraviolet-uisible spectrophotometers (Shanghai Precision Scientific Apparatus Co., Ltd); Centrifuge LXJ-IIB (Anting Scientific Instrument Factory, Shanghai); Electronic balance BS-124S (Beijing Sai Duolisi instrument system company limited).
4. experimental technique
4.1 cause the impact of blood glucose in diabetic mice and blood fat to alloxan
The freshly prepared alloxan 50mg/kg of mouse tail vein injection causes diabetes model, after 72h.Fasting be can't help to the mouse orbit rear vein beard blood sampling of water, survey blood glucose value, choose the mice of fasting glucose higher than 11.1mmol/L for experiment.Get qualified model mice 40, be divided into 4 groups at random, glibenclamide group (10), pharmaceutical composition 1, pharmaceutical composition 4 (often organizing each 10), diabetic model group, separately gets the normal mouse of similar weight as normal group (10).After successive administration 14d. before last administration, water 8h is can't help in mice fasting, continue fasting after administration and can't help 2h after water, pluck eyeball and get blood, measure the fasting blood sugar of each group, total cholesterol level, triacylglycerol content, hdl concentration, low density lipoprotein, LDL content.
4.2 cause the impact of blood glucose in diabetic mice to epinephrine
Get qualified Kunming mouse 60 (male and female half and half), be divided into 4 groups at random, pharmaceutical composition 1, pharmaceutical composition 4 (often organizing 10) and glibenclamide group (10) dosage same " 4.1 ", model group (10) and normal group (10) gavage equal-volume normal saline. successive administration 10d.Before last administration, water 8h is can't help in mice fasting, and continue after fasting can't help water 6h after administration, except matched group, every mouse peritoneal Injection of Adrenaline 0.2mg, Normal group is the capacity normal saline such as lumbar injection then.After 30min, retroorbital venous clump is taken a blood sample, and measures the fasting blood sugar of each group.
4.3 statistical procedures
Experimental data mean ± standard deviation represents, makes t check the significance comparing group difference.
5. result
5.1 cause the impact of blood glucose in diabetic mice to alloxan
After successive administration 14d, the mouse blood sugar value of pharmaceutical composition 1, pharmaceutical composition 4 all has significance to decline (P<0.05) compared with model group, with glibenclamide group mouse blood sugar value no significant difference (P>0.05), the results are shown in Table 1.
Table 1 pharmaceutical composition is on the impact of alloxan diabetes mouse blood sugar
Note: compare with normal group,
#p<0.05; Compare with model group,
*p<0.05.
5.2 cause the impact of blood glucose in diabetic mice to epinephrine
After administration 10d, lumbar injection adrenalin hydrochloride, model group mouse blood sugar value is significantly higher than normal group (P<0.05); Administration group mouse blood sugar value is all remarkable in model group (P<0.05), does not have significant difference (P>0.05) with glibenclamide group.The results are shown in Table 2.
Table 2 pharmaceutical composition is on the impact of epinephrine blood glucose in diabetic mice
Note: compare with Normal group,
#p<0.05; Compare with model control group,
*p<0.05.
5.3 cause the impact of diabetic mice blood lipid level to alloxan
After administration 14d. compare with normal group, diabetic groups mice TC, TG, LDL-C content significantly raises (P<0.05), and HDL-C content significantly declines (P<0.05); Compare with model group, administration group mice TG, LDL-C content significantly declines (P<0.05), and HDL-C content significantly raises (P<0.05).In table 3.
Table 3 pharmaceutical composition is on the impact of alloxan diabetes lipid of mice
Note: compare with normal group,
#p<0.05; Compare with model group,
*p<0.05.
Result shows: pharmaceutical composition of the present invention has remarkable hypoglycemic activity to diabetic mice, can regulate diabetic mice blood lipid level simultaneously.Compare with model group, pharmaceutical composition of the present invention significantly can reduce alloxan and cause blood glucose in diabetic mice value (P<0.05), and significantly can reduce epinephrine and cause blood glucose in diabetic mice value (P<0.05).Pharmaceutical composition group mice triacylglycerol of the present invention, low density lipoprotein, LDL content significantly decline (P<0.05), and hdl concentration significantly raises (P<0.05).
Claims (6)
1. treat a pharmaceutical composition for diabetes, it is characterized in that: be made up of following crude drug by weight: 3-7 part, wall tapestry 2-4 part, fruit of Cordia dichotoma Forst. f. 3-5 part, the Aleuritopteris argentea (Gmel.) Fee 2-4 parts such as Radix Berberidis Amurensis fruit 8-15 part, Spiraea alpina 4-6 part, Song Sheng.
2. a kind of pharmaceutical composition for the treatment of diabetes according to claim 1, is characterized in that: be made up of following crude drug by weight: Radix Berberidis Amurensis fruit 10 parts, Spiraea alpina 5 parts, Song Sheng etc. 5 parts, wall tapestry 3 parts, fruit of Cordia dichotoma Forst. f. 4 parts, Aleuritopteris argentea (Gmel.) Fee 3 parts.
3. treat the preparation method of the pharmaceutical composition of diabetes for one kind, it is characterized in that: by weight, Radix Berberidis Amurensis fruit 10 parts, Spiraea alpina 5 parts, Song Sheng etc. 5 parts, wall tapestry 3 parts, fruit of Cordia dichotoma Forst. f. 4 parts, Aleuritopteris argentea (Gmel.) Fee 3 parts, mixing, with water extraction, Extracting temperature 50 DEG C-100 DEG C, extraction time is 1-4 time, each extraction time is 1-4 hour, and each solvent load is 6-15 times of each crude drug gross weight; Filter, merge extractive liquid, concentrated, dry, to obtain final product.
4. a kind of preparation method for the treatment of the pharmaceutical composition of diabetes according to claim 3, it is characterized in that: by weight, Radix Berberidis Amurensis fruit 10 parts, Spiraea alpina 5 parts, Song Sheng etc. 5 parts, wall tapestry 3 parts, fruit of Cordia dichotoma Forst. f. 4 parts, Aleuritopteris argentea (Gmel.) Fee 3 parts, mixing, with water extraction, Extracting temperature 93 DEG C, extraction time is 2 times, each extraction time is 2 hours, and each solvent load is 12 times of each crude drug gross weight; Filter, merge extractive liquid, concentrated, dry, to obtain final product.
5. powder or tablet or pill or a capsule, it is characterized in that being made up by the various adjuvants adding pharmaceutics and allow of pharmaceutical composition according to claim 1 or claim 2.
6. the medicine of the treatment diabetes formed with chemical drugs or natural drug according to pharmaceutical composition according to claim 1 or claim 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310525436.8A CN103585312B (en) | 2013-10-31 | 2013-10-31 | A kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310525436.8A CN103585312B (en) | 2013-10-31 | 2013-10-31 | A kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103585312A CN103585312A (en) | 2014-02-19 |
| CN103585312B true CN103585312B (en) | 2016-04-20 |
Family
ID=50075766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310525436.8A Expired - Fee Related CN103585312B (en) | 2013-10-31 | 2013-10-31 | A kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103585312B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102366480A (en) * | 2011-09-28 | 2012-03-07 | 久美彭措 | Medicine for treating diabetes and preparation method thereof |
-
2013
- 2013-10-31 CN CN201310525436.8A patent/CN103585312B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102366480A (en) * | 2011-09-28 | 2012-03-07 | 久美彭措 | Medicine for treating diabetes and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 藏药及饮食治疗糖尿病伴继发性肾性尿崩症2例;尕藏本;《中国民族医药杂志》;20100930(第09期);第42页 * |
| 藏药降糖舒胶囊对四氧嘧啶糖尿病小鼠的防治作用研究;张涓等;《时珍国医国药》;20091231;第20卷(第05期);第1222-1223页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103585312A (en) | 2014-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103719498B (en) | A kind of Siberian solomonseal rhizome health-care tea improving immunity and preparation method thereof | |
| CN103285231B (en) | Medicine composition for diabetes adjunctive therapy and preparation method thereof | |
| CN104435775A (en) | Chinese medicinal health-care spirit and preparation method thereof | |
| CN103637179B (en) | Food composition with functions of lowering blood sugar and blood fat and improving fatty liver | |
| CN103690784B (en) | The Chinese medicine composition for the treatment of Complicating with Hypentersion nephropathy and preparation method | |
| CN103301413A (en) | Traditional Chinese medicine composition for treating hyperlipemia and hyperglycemia | |
| CN103223111A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof | |
| CN102885975A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN111919982A (en) | Natural plant beverage for relieving alcoholism and preparation method thereof | |
| CN103749819A (en) | Cornus officinalis sieb health-care tea capable of lowering blood sugar and lowering lipid and preparation method of tea | |
| CN104434941A (en) | Medicine composition for treating diabetes | |
| CN107412462B (en) | Preparation method of Huanglong cough and asthma capsule | |
| CN103599211B (en) | A kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof | |
| CN104524167A (en) | Traditional Chinese medicine preparation for treating liver cirrhosis and liver ascites and preparation method of traditional Chinese medicine preparation | |
| CN103585234B (en) | The application of Radix Berberidis Amurensis berry extract in preparation treatment diabetes medicament | |
| CN103585312B (en) | A kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof | |
| CN104958615B (en) | A kind of Chinese medicine composition of prevention and treatment II diabetes and preparation method thereof | |
| CN105327115B (en) | A kind of prevention and treatment type II diabetes Phellinus is logical to rush down formula and preparation process | |
| CN103977390A (en) | Method for preparing ginger-onion medicinal liquor composition and application thereof | |
| CN103705860A (en) | Traditional Chinese medicine composition for treating infant jaundice and preparation method thereof | |
| CN103585302B (en) | The application of the extracts such as a kind of Song Sheng in preparation treatment diabetes medicament | |
| CN103585198B (en) | The preparation method of mesh Herba Lepisori Thunbergiani extract and application thereof | |
| CN103585205B (en) | The application of a kind of Chrysosplenium extract in preparation treatment diabetes medicament | |
| CN106075038B (en) | A kind of preparation method and application of pulse-invigorating and heart-nourishing pill | |
| CN104096073A (en) | Traditional Chinese medicine composition for treating male infertility and preparation method for same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: HUANG CAIFENG Free format text: FORMER OWNER: JINAN XINGYI MEDICAL TECHNOLOGY CO., LTD. Effective date: 20150713 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Huang Caifeng Inventor after: Wang Hongzhen Inventor after: Yu Shuqiong Inventor before: Kong Qianqian |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: KONG QIANQIAN TO: HUANG CAIFENG WANG HONGZHEN YU SHUQIONG |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150713 Address after: Derek street in Jimo City, Shandong province 266000 Qingdao City No. 4 Applicant after: Huang Caifeng Address before: 250101 No. 51 Industrial South Road, Ji'nan hi tech Zone, Shandong, Ji'nan Applicant before: Jinan Xingyi Medical Technology Co.,Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160420 Termination date: 20161031 |